Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)

NCT05833711 is registered in ClinicalTrials.gov with Immunoforge Co. Ltd. as lead sponsor.

NCT NCT05833711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05833711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy (IIM)
Lead sponsor
Immunoforge Co. Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
September 5, 2023
Completion date
September 30, 2025
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, idiopathic inflammatory myopathies, polymyositis